SmartTRAK Life Sciences News and Analysis Blog in the Orthopedics, Wound, and Neuro Therapies Market Segments
.png)
Q122 started slow but ended on a bright note as COVID-19 concerns faded and surgical volumes approached ...
Wallaby Medical CEO and founder Michael Alper discusses the Company’s recent acquisition of phenox GmBH ...
US Viscosupplementation Market players march on the positive momentum of Q421 and Q122, putting the spri...
Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Com...
SmartTRAK reports that challenging conditions lead to minimal innovation in Paris. It was third time luc...
Q122 SCS Market revenues were up in the low-single digit YoY, but pandemic-related issues made it a bump...
Spinal Elements provides an in-depth look at the Company’s novel Karma Fixation System and what’s next f...
The return of elective procedure volumes, new product offerings and a busy first quarter of acquisitions...
Soft Tissue Fixation Rebounds in Q122 After a slow end to 2021, Soft Tissue Fixation bounced back with p...
Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with Smart...
Login